guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1[J]. BMJ Open, 2022, 12(3): e055821.
[8]. Xu B, Ma F, Wang S, et al. Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–...
[10]Pernas S, Im S, Hattori M, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (B...
对于没有靶向突变的患者,Stringer-Reasor总结道,氟维司群单药疗法仍然是标准治疗,尽管有希望的数据支持基于依维莫司的方案与依西美坦或氟维司群联合使用。 参考文献: Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena.onclive.com/view/target ...
5、FC Bidard, et al. Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. 2021 San Antonio Breast Cancer Symposium, GS3-05....
2. Chen Z, et al. Is HER2 ultra‑low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients. Breast Cancer Res Treat. 2023 Nov;202(2):313-323. 3. Manohar P, et al. Updates in endocrine therapy for metastatic breast cancer. Cancer Biol Med. 20...
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res. 2021 Mar 24;23(1):37. 6.Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-...
[2].Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 Mar 1;26(5):1105-1113.[3].Rugo HS, Rumble RB, Macrae E, ...
[3]、Cristofanilli, Massimo et al. “Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 random...
DESTINY-Breast06研究新突破,拓展抗HER2治疗获益人群。 美国临床肿瘤学会(ASCO)年会于2024年5月31日至6月4日在美国芝加哥盛大召开,本次大会公布了多项乳腺癌领域的最新成果,其中德曲妥珠单抗(T-DXd)作为HER2靶向的代表性ADC药物更是讨论的热点。T-DXd是首个在HER2低表达乳腺癌领域开展III期临床试验并取得阳性结果的...